Display options
Cite
Sezer OB, Sezer T. A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate. J Neurogastroenterol Motil. 2016;22(4):656-660doi: 10.5056/jnm16035.
Sezer, O. B., & Sezer, T. (2016). A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate. Journal of neurogastroenterology and motility, 22(4), 656-660. https://doi.org/10.5056/jnm16035
Sezer, Oya B, and Sezer, Taner. "A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate." Journal of neurogastroenterology and motility vol. 22,4 (2016): 656-660. doi: https://doi.org/10.5056/jnm16035
Sezer OB, Sezer T. A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate. J Neurogastroenterol Motil. 2016 Oct 30;22(4):656-660. doi: 10.5056/jnm16035. PMID: 27302967; PMCID: PMC5056575.
Copy Download .nbib Format: NLM
Share it on

J Neurogastroenterol Motil. 2016 Oct 30;22(4):656-660. doi: 10.5056/jnm16035.

A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate.

Journal of neurogastroenterology and motility

Oya B Sezer, Taner Sezer

Affiliations

  1. Department of Pediatric Gastroenterology and Nutrition, Kecioren Training and Research Hospital, Ankara, Turkey.
  2. Department of Pediatric Neurology, Baskent University Faculty of Medicine, Ankara, Turkey.

PMID: 27302967 PMCID: PMC5056575 DOI: 10.5056/jnm16035

Abstract

BACKGROUND/AIMS: The aim of this study was to compare the efficacy and tolerability of topiramate and propranolol in preventing pediatric cyclic vomiting syndrome.

METHODS: A retrospective medical-record review of patients who underwent prophylaxis after receiving a diagnosis of cyclic vomiting syndrome was performed. Patients who completed at least 12 months of treatment were included in the analysis. Responder rate, and adverseevent rates were also calculated from all patients. Response to treatment was assessed as the total number of vomiting attacks per year. Patients in whom the frequency of vomiting attack reduced greater or equal to 50% were defined as responders, and the remaining patients were classified as nonresponders.

RESULTS: A total of 38 patients who were treated prophylactically with either topiramate (16 patients) or propranolol (22 patients) were identified. Fifty-nine percent of the patients in the propranolol group and 81% of the patients in the topiramate group reported freedom from attacks. A decrease of more than 50% in attacks per year occurred in 23% of patients in the propranolol group and 13% of patients in the topiramate group. The responder rates were 81% for propranolol group and 94% for topiramate group (

CONCLUSIONS: The efficacy of topiramate was superior to propranolol for the prophylaxis of pediatric cyclic vomiting syndrome.

Keywords: Cyclic vomiting syndrome; Propranolol; Topiramate

References

  1. Am J Gastroenterol. 2008 Apr;103(4):991-5; quiz 996 - PubMed
  2. Neurogastroenterol Motil. 2008 Apr;20(4):269-84 - PubMed
  3. J Med Assoc Thai. 2002 Aug;85 Suppl 2:S743-8 - PubMed
  4. J Pediatr Gastroenterol Nutr. 1997 Jul;25(1):64-7 - PubMed
  5. Neurogastroenterol Motil. 2011 May;23(5):439-43 - PubMed
  6. Gastroenterology. 2006 Apr;130(5):1377-90 - PubMed
  7. BMC Gastroenterol. 2012 May 28;12:52 - PubMed
  8. Brain Dev. 2009 Jun;31(6):411-3 - PubMed
  9. Pediatrics. 1997 Dec;100(6):977-81 - PubMed
  10. J Pediatr Gastroenterol Nutr. 1995;21 Suppl 1:S60-2 - PubMed
  11. World J Gastroenterol. 2007 Mar 28;13(12):1833-6 - PubMed
  12. BMC Neurol. 2011 Aug 16;11:102 - PubMed
  13. Indian J Pediatr. 2009 Dec;76(12):1261-2 - PubMed
  14. Indian J Physiol Pharmacol. 1993 Jan;37(1):67-70 - PubMed
  15. J Pediatr Gastroenterol Nutr. 2008 Sep;47(3):379-93 - PubMed
  16. J Neurogastroenterol Motil. 2010 Apr;16(2):139-47 - PubMed
  17. Seizure. 2013 Oct;22(8):589-600 - PubMed
  18. Pediatr Neurol. 2006 Nov;35(5):348-51 - PubMed
  19. J Clin Gastroenterol. 2006 Nov-Dec;40(10):896-8 - PubMed
  20. J Pediatr Gastroenterol Nutr. 1995;21 Suppl 1:S57-9 - PubMed

Publication Types